New antibody EPI-326 enters first human trials for tough cancers
Disease control
Recruiting now
This early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC